Charles River Laboratories International (NYSE:CRL) EVP Sells $302,579.64 in Stock

Posted by Geri Gentry on Oct 10th, 2026

Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) EVP Shannon Parisotto sold 981 shares of the firm’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $308.44, for a total value of $302,579.64. Following the completion of the sale, the executive vice president owned 4,807 shares of the company’s stock, valued at approximately $1,482,671.08. This represents a 16.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Stock Up 1.4%

Charles River Laboratories International stock opened at $302.24 on Friday. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92. The firm’s fifty day moving average price is $284.42 and its two-hundred day moving average price is $222.76. The firm has a market capitalization of $14.43 billion, a price-to-earnings ratio of -62.32, a price-to-earnings-growth ratio of 2.79 and a beta of 1.40. Charles River Laboratories International, Inc. has a 1-year low of $146.20 and a 1-year high of $333.30.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.25. The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The firm’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter last year, the firm earned $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, equities research analysts predict that Charles River Laboratories International, Inc. will post 11.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

CRL has been the topic of a number of recent analyst reports. Zacks Research raised shares of Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 2nd. UBS Group assumed coverage on shares of Charles River Laboratories International in a research note on Wednesday, September 30th. They issued a “buy” rating and a $357.00 price objective for the company. Morgan Stanley lifted their target price on shares of Charles River Laboratories International from $260.00 to $300.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Royal Bank Of Canada upped their target price on Charles River Laboratories International from $282.00 to $322.00 and gave the company an “outperform” rating in a report on Friday, September 25th. Finally, Piper Sandler set a $300.00 price target on Charles River Laboratories International in a research report on Monday, August 10th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $300.11.

View Our Latest Stock Analysis on CRL

Hedge Funds Weigh In On Charles River Laboratories International

Several institutional investors have recently bought and sold shares of the company. Continuum Advisory LLC purchased a new position in shares of Charles River Laboratories International during the 2nd quarter valued at $30,000. SHP Wealth Management purchased a new stake in Charles River Laboratories International in the 4th quarter worth about $85,000. Trust Asset Management LLC bought a new stake in Charles River Laboratories International in the 2nd quarter valued at about $129,000. Hilltop National Bank lifted its holdings in Charles River Laboratories International by 28.7% during the second quarter. Hilltop National Bank now owns 569 shares of the medical research company’s stock valued at $129,000 after purchasing an additional 127 shares during the last quarter. Finally, Integrated Wealth Concepts LLC purchased a new stake in Charles River Laboratories International during the second quarter valued at about $172,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

(Get Free Report)

Charles River Laboratories International, Inc is a contract research organization that provides products and services to support pharmaceutical, biotechnology and academic research. The company helps customers discover, develop and manufacture new medicines, vaccines and other healthcare products.

Its offerings include research models and related services, preclinical drug discovery, pharmacology, toxicology, bioanalysis and safety assessment. Charles River also provides laboratory and manufacturing solutions for biologics, cell and gene therapies, microbial testing and other specialized life sciences applications.

Founded in 1947, Charles River Laboratories serves customers worldwide through operations across North America, Europe and Asia.